Medical costs of treating myasthenia gravis in patients who need intravenous immunoglobulin (IVIg) – a register-based study
Christoffer Bugge, Ingrid Engebretsen, Ivar Sønbø Kristiansen, Erik Magnus Sæther, Ingrid Lindberg-Schager, Fredrik Arneberg, Nils Erik Gilhus · 2024
Read Medical costs of treating myasthenia gravis in patients who need intravenous immunoglobulin (IVIg) – a register-based study by Christoffer Bugge, Ingrid Engebretsen, Ivar Sønbø Kristiansen, Erik Magnus Sæther, Ingrid Lindberg-Schager, Fredrik Arneberg, Nils Erik Gilhus (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11638270.txt.
Description
Christoffer Bugge and co-authors measure the medical costs of treating a muscle weakness disease in Norway, in a study from 2024. The disease, called myasthenia gravis, is treated in some patients with a blood product given through a vein. New treatments are on the way, and payers will need cost data to judge them.
The team used a national patient registry covering more than a decade. Just over one thousand patients with the disease were found, and about one in seven had the vein treatment. Those patients cost far more than the others in the first years after diagnosis, more than twice as much in the first year and more in the second. Costs stayed higher even five years on. Age and sex were much the same in both groups.
Catalog record
| CREATOR | Christoffer Bugge, Ingrid Engebretsen, Ivar Sønbø Kristiansen, Erik Magnus Sæther, Ingrid Lindberg-Schager, Fredrik Arneberg, Nils Erik Gilhus |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |